Aclarion
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 6
- Market Cap
- -
- Introduction
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes
- Conditions
- Discogenic Low Back Pain
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Aclarion
- Target Recruit Count
- 300
- Registration Number
- NCT06661850
- Locations
- 🇺🇸
Scripps Health, La Jolla, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Advocate Aurora Research Institute, Park Ridge, Illinois, United States
News
USC Spine Center Joins Pivotal CLARITY Trial to Evaluate Nociscan for Chronic Low Back Pain
Keck Medical Center of USC has joined the CLARITY trial to evaluate Aclarion's Nociscan technology, which uses MR Spectroscopy and AI to identify sources of chronic low back pain.
Northwestern Medicine Selected as First Site for Pivotal CLARITY Trial Testing Nociscan's Low Back Pain Technology
Northwestern Medicine, a leading clinical research institution that conducted over 6,900 studies in 2024, has been selected as the initial site for Aclarion's CLARITY trial investigating Nociscan technology.
Aclarion Expands CLUE Trial for Nociscan in Chronic Low Back Pain Diagnosis
Aclarion's CLUE trial, evaluating Nociscan's impact on chronic low back pain treatment, expands to New Jersey with Dr. Justin Kubeck joining the study.